Old Blood Pressure Drug Helps Kids With Rare Brain Disease

For families facing vanishing white matter disease, watching their young children lose the ability to walk has been heartbreaking and inevitable. Now, a decades-old blood pressure pill is changing that story.

Researchers in Amsterdam tested guanabenz on 33 children with this rare brain disease and found stunning results. Only 21% of kids taking the medication lost their ability to walk with support over four years, compared to 44% of untreated children. That's a 67% lower risk of this devastating milestone.

Vanishing white matter typically strikes between ages 1 and 6. The disease destroys protective tissue in the brain, leading to severe disability and early death. Until now, doctors could only watch it progress.

The drug works by blocking a harmful stress response that damages brain cells in these children. Scientists had seen it help mice with the condition, but this is the first time anyone tested whether it could help human patients.

The children who benefited most were those who got sick at age 3 or later. In that group, only one of 18 kids on guanabenz lost walking ability, compared to 11 of 36 untreated children. Starting treatment early appears to prevent decline rather than reverse damage already done.

Dr. Margo van der Knaap, who led the study at Amsterdam UMC, emphasized that guanabenz mostly stops further deterioration. Her team is now exploring whether treating children before symptoms appear could prevent the disease from manifesting at all.

The medication did cause side effects. More than half the children experienced hallucinations, mostly at night during the first few months. These typically went away on their own with reassurance, though three kids needed a low dose of another medication to help. No children stopped treatment because of side effects, and there were no life-threatening reactions.

Why This Inspires

This breakthrough matters beyond the small number of families affected by vanishing white matter disease. It shows that repurposing existing medications can unlock treatments for rare conditions that might otherwise never attract drug development investment.

Guanabenz costs pennies per pill because its patent expired decades ago. No pharmaceutical company had financial incentive to test it for this use, yet researchers pursued it anyway because the science made sense and families desperately needed options.

Dr. Geneviève Bernard of Montreal Children's Hospital noted that other treatments are in development too, including gene therapy. The hope is that combination approaches might one day offer even better outcomes for these children.

Parents who once faced only decline now have reason to plan for their children's futures.